In early 2026, news of a once-nightly sleep apnea pill landed on social media and people were pretty excited. People suffering from sleep apnea who don’t like using CPAP would be eager to swap the machine for the simplicity of a pill.
In this article, I’ll explain what the sleep apnea pill does, how effective it was in the SynAIRgy trial, and when it might become available.
What is the Sleep Apnea Pill?
The sleep apnea pill mentioned in the news currently goes by the name AD109. It combines two drugs, aroxybutynin and atomoxetine, into one pill taken at bedtime. Both of these drugs work by affecting the action of neurotransmitters- chemical messages sent from nerve cells to other cells, including those of nerves, muscles, and glands. Aroxybutynin affects the action of the neurotransmitter acetylcholine, and atomoxetine affects the neurotransmitter norepinephrine.
The action of AD109 on the body is different from what we see with other sleep apnea therapies. Instead of holding the airway open with CPAP, adjusting tissue through surgery, or stimulating the hypoglossal nerve directly, AD109 activates the control center for the hypoglossal nerve to keep the tongue muscles active. These muscles relax during sleep; for people with sleep apnea, they may relax too much and block the airway.
Apnimed, the company that developed AD109 and sponsored the studies published thus far, has made the claim that obstructive sleep apnea is a neuromuscular problem which AD109 addresses. This is somewhat misleading. While lower airway muscle tone does contribute to airway collapse, fat deposition in the tongue and soft tissues of the airway plays a much bigger role for most people in causing the airway to collapse.
What We Know About How Well the Sleep Apnea Pill Performs
In the published SynAIRgy trial, AD109 lowered the apnea hypopnea index (AHI), which measures how many times a person stops breathing or struggles to breathe, each hour during sleep. Participants took AD109 or placebo for 6 months. The AHI went down by an average of 4 points compared to placebo. About 1 out of 4 participants taking AD109 had a 50% or more reduction in AHI. The number of times oxygen levels dropped per hour of sleep was reduced by an average of 4.5.
While the average reductions in AHI were low, the data included everyone who had taken at least one dose of AD109. So if a participant took one dose, 10 doses, or 180 doses, the results were included.
To try to see what the result might have been if everyone took AD109 as instructed for the full 6 months, additional statistical analyses were done. If you had a sleep study after taking at least one dose of AD109 and then were never heard from again, the researchers just filled in the missing data with the data from that sleep study and recalculated the results.
This created a model of what might have happened if everyone took the drug for the full 180 days. As expected, the data looks a bit better. The AHI went down by an average of 6.5 points compared to placebo. Four out of 10 participants taking AD109 had a 50% or more reduction in AHI. The number of times oxygen levels dropped per hour of sleep was reduced by an average of 7.2.
While these estimates are better, they still show a relatively small change in average AHI with AD109. The majority of people taking the drug would continue to need additional therapy to adequately treat their sleep apnea.
Many people in both studies complained of side effects with AD109. These included insomnia, dry mouth, difficulties urinating, and nausea. Over 20% of the participants stopped taking the drug because of side effects. Additionally, the sleep studies showed that people taking AD109 had higher heart rates, less total sleep time, and less REM sleep. These side effects are likely due to the atomoxetine which mimics the effect of noradrenaline.
I think weight loss medications such as tirzepetide (Zepbound, Mounjaro) are a bigger breakthrough for sleep apnea than AD109. Most cases of sleep apnea are caused by excess fat in the soft tissues of the tongue and throat. The SURMOUNT trail showed that obese people taking tirzepetide lost about 40 pounds, and their average AHI decreased by 20- 25. Nearly half of the participants were cured with weight loss.
AD109 may be an option for some people or be useful if combined with other therapies. However, given the small improvements in AHI and oxygen levels and the significant side effects, I’m not sure yet exactly how it will fit into our treatment plans.
Where the Sleep Apnea Pill Currently Stands
As of this writing, AD109 isn’t FDA-approved and is not available to prescribe in the United States or elsewhere.
Following the publication of the SynAIRgy trial results in May 2026, Apnimed AD109, sent a New Drug Application to the FDA. The FDA plans to have a decision regarding approval by February 28, 2027.
Once approved, I would not expect the drug to be available for several months. Many people with certain health conditions and taking specific medications will not be able to take AD109 because of an increased risk of side effects.
What Can You Do Now
You don’t have to wait for a pill that isn’t currently available to get help. Depending on the factors causing your apnea, there are effective treatments that are available now. These include CPAP, oral appliances, tirzepetide, or surgeries like Inspire, Genio, or airway procedures.
The Bottom Line on the Sleep Apnea Medication
I’m always interested to see new developments in sleep apnea treatments, including medications. Some medications, like tirzepetide, are already an option for certain patients. However, AD109 alone is not likely to be the solution for most people looking for alternatives to CPAP.
If you’re having trouble with your current treatment, don’t wait for a medication that isn’t here. Let’s focus on what can help you sleep better right now.
References:
Strollo PJ, Farkas R, Taranto-Montemurro L, et al. Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy). American Journal of Respiratory and Critical Care Medicine. Published online May 18, 2026. DOI: 10.1093/ajrccm/aamag215
Apnimed, Inc. Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA). Press release. July 14, 2026.
Disclaimer: As of August 24, 2026 AD109 is not yet approved by the FDA and is not currently available for prescription. The information on this page is for educational purposes only and reflects the status of AD109 as of the publication date. Talk to Dr. Weiner or your doctor about which sleep apnea treatments are right for you.
Sleep Apnea in Women FAQ
What is a witnessed apnea?
A witnessed apnea is when another person, usually a bed partner, sees a pause in their loved one’s breathing during sleep, sometimes followed by a snort, gasp, or choking sound when breathing begins again. The person experiencing the apnea usually has no memory of it happening, which is why a partner’s account is often the first clue something is wrong.
How common is sleep apnea in women?
Sleep apnea is often underdiagnosed in women because their symptoms differ from the classic presentation seen in men. Rather than loud snoring and daytime sleepiness, women more often report fatigue, insomnia, and morning headaches, which can delay diagnosis for years.
What causes sleep apnea in women?
Weight is the single biggest cause of sleep apnea in both men and women. In younger, premenopausal women, sleep apnea is usually tied to weight, though age and hormones play a role as well.
How does menopause affect sleep apnea risk?
Estrogen helps maintain tone in the muscles that keep the airway open. When estrogen drops during menopause, that support drops with it, and the airway is at greater risk of narrowing or collapsing during sleep.
Why do sleep studies sometimes miss sleep apnea in women?
Women may have sleep-related breathing disorders that affect their quality of life but don’t register as full apneas or hypopneas on a standard sleep study. Restricted airflow that falls short of that threshold can still cause fragmented sleep, fatigue, brain fog, and memory problems.